MedPath

A comparative study of two different doses of magnesium sulphate pre-treatment on the onset and duration of rocuronium induced neuromuscular blockade, A randomised controlled double blinded study.

Not yet recruiting
Conditions
Medical and Surgical,
Registration Number
CTRI/2023/03/051103
Lead Sponsor
Dr.Anand
Brief Summary

Rapid sequence induction usually applies when tracheal intubation must be performed in a patient who is suspected of having a full stomach and who is at risk of pulmonary aspiration of gastric contents. The goal is to secure the airway without producing any regurgitation or vomiting. The second objective involves minimization of induction–intubation interval, which means that a short-acting hypnotic agent should be administered with a rapidly acting neuromuscular-blocking agent.

Rocuronium, a nondepolarizing muscle relaxant, has been shown to provide adequate intubating conditions with rapid onset, an intermediate duration and no obvious side effects. Rocuronium produces faster neuromuscular blockade compared with other nondepolarizing neuromuscular-blocking drugs.

Magnesium potentiates neuromuscular blockade through the inhibition of calcium-mediated release of acetylcholine from the presynaptic nerve terminals at the neuromuscular junction and also a decrease in postsynaptic sensitivity to acetylcholine and direct effects on the membrane potential of myocytes, thus augmenting the effect of nondepolarizing neuromuscular blockers.

After pre-treatment with magnesium sulphate (MgSO4), an increased speed of onset and a prolongation of the recovery period of neuromuscular blockade have been observed with atracurium and vecuronium.

It may be assumed that the effect of the magnesium ion on the neuromuscular endplate is both concentration and time dependent.

Magnesium infusion, rather than a bolus injection immediately before the injection of the NMBA, has an impact on neuromuscular blockade. In theory, MgSO4 pre-treatment should reduce the onset time of a rocuronium-induced block to an extent that makes it an interesting alternative to succinylcholine for rapid sequence induction.

After institutional human ethical commitee approval and CTRI registration. patients with in the inclusion criteria are selected.

Totally 90 patients will be participating in this study under three groups with each group containing 30 patients.

GROUP 1: n=30

Infusion of 50 mg/kg of magnesium sulphate will be given over 10 min prior to induction with 0.6 mg/kg of rocuronium.

GROUP 2: n=30

Infusion of 60 mg/kg of magnesium sulphate will be given over 10 min prior to induction with 0.6 mg/kg of rocuronium.

GROUP 3: n=30

Infusion of 100ml normal saline will be given over 10 min prior to induction with 0.6 mg/kg of rocuronium, will be considered as the control group.

and the onset and duration of rocuronium induced neuromuscular blockade is noted with TOF monitor and results are noted.

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
All
Target Recruitment
90
Inclusion Criteria

ASA Grade I and Grade II patients Mallampatti Grade I and Grade II.

Exclusion Criteria
  • Refusal of consent Known or anticipated difficult airway.
  • Emergency surgeries.
  • Pregnant patients.
  • Patients with a BMI of 35 or more Patients with significant hepatic, renal, metabolic, neuro-muscular disorder Those with allergy to Rocuronium.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To compare two different doses of magnesium sulphate pre-treatment on the onset of rocuronium induced neuromuscular blockadeIt is assessed every 30 sec with TOF monitoring. | Onset is noted when TOF becomes zero.
Secondary Outcome Measures
NameTimeMethod
To compare two different doses of magnesium sulphate pre-treatment on the duration of rocuronium induced neuromuscular blockade and haemodynamic changes.It is monitored every 2 minutes .Duration of action is determined when TOF zero becomes TOF 1

Trial Locations

Locations (1)

Chettinad hospital and research institute

🇮🇳

Kancheepuram, TAMIL NADU, India

Chettinad hospital and research institute
🇮🇳Kancheepuram, TAMIL NADU, India
Ramya J
Principal investigator
7708120186
ramyajawahar417@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.